Cipla Signals Lanreotide Supply Strain, Eyes First Wave GLP-1 India Entry

Cipla Scion To Shepherd ‘Value Systems, Growth Agenda’

 
• By Anju Ghangurde
  
Supply issues for key peptide asset may slow Cipla's earnings run

More from Earnings

More from Strategy